PreOmics GmbH and Biognosys AG Prevail in U.S. Patent Challenge
Bruker Corporation (BRKR)
Last bruker corporation earnings: 10/31 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.bruker.com/investors/default.aspx
Company Research
Source: Business Wire
US PTAB Revokes Sole Independent and Other Central Claims of U.S. Patent 11,435,360 SCHLIEREN, Switzerland & MUNICH--(BUSINESS WIRE)--PreOmics GmbH and Biognosys AG today announced a favorable outcome in an inter partes review (IPR) proceeding IPR2024-01473 before the U.S. Patent Trial and Appeal Board (PTAB). The PTAB has revoked the central claims of U.S. Patent No. 11,435,360, which is owned by The Brigham and Women’s Hospital, and exclusively licensed to Seer, Inc.The USPTO struck down the sole independent claim of the ‘360 patent, among other claims. The PTAB specifically invalidated Claim 1, which attempted to cover workflows using multiple nanoparticle types to form biomolecule coronas and detect proteins across a wide dynamic range.“This outcome confirms what we have consistently believed from the outset: the fundamental concepts at issue were already known in the scientific literature,” said Dr. Oliver Rinner, co-founder and managing director of Biognosys AG. “We welcome t
Show less
Read more
Impact Snapshot
Event Time:
BRKR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BRKR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BRKR alerts
High impacting Bruker Corporation news events
Weekly update
A roundup of the hottest topics
BRKR
News
- Bruker (BRKR) had its price target lowered by Guggenheim from $58.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Bruker (BRKR) had its "sell (d+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Here's Why Bruker's (BRKR) Positive Momentum Returned in Q4 [Yahoo! Finance]Yahoo! Finance
- Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XRBusiness Wire
- Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic ApplicationsBusiness Wire
BRKR
Earnings
- 2/12/26 - Miss
BRKR
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/16/26 - Form 4
- 3/13/26 - Form 144
- BRKR's page on the SEC website